Jianping Chen, MD
Psychiatry · New York, NYNPI 1245229814
Payments from drug & device makers
Across 2,384 payments — averaging $485.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$255K
- Otsuka America Pharmaceutical, Inc.$230K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$180K
- Teva Pharmaceuticals USA, Inc.$152K
- Axsome Therapeutics, Inc.$111K
- Vanda Pharmaceuticals Inc.$81K
- plus $148K from 19 others
What the payments were for
- Consulting fees$94,4298%
- Speaking & faculty fees$921,77680%
- Travel & lodging$74,7916%
- Food & beverage$65,5686%
- Education$5050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 332 | $254,664 |
| Otsuka America Pharmaceutical, Inc. | 401 | $230,249 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 296 | $179,803 |
| Teva Pharmaceuticals USA, Inc. | 285 | $152,438 |
| Axsome Therapeutics, Inc. | 163 | $110,590 |
| Vanda Pharmaceuticals Inc. | 86 | $80,933 |
| AbbVie(2 entities) | 174 | $47,498 |
| E.r. Squibb & Sons, L.L.C. | 54 | $30,800 |
| Takeda Pharmaceuticals U.S.A., Inc. | 121 | $23,292 |
| Idorsia Pharmaceuticals US Inc | 29 | $15,805 |
| Indivior Inc. | 47 | $13,826 |
| Neurocrine Biosciences, Inc. | 211 | $10,414 |
| Sunovion Pharmaceuticals Inc. | 26 | $3,698 |
| Lundbeck LLC | 132 | $1,906 |
| Johnson & Johnson | 8 | $215 |
| Gilead | 1 | $125 |
| Bayer | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| Eisai Inc. | 1 | $121 |
| Boehringer Ingelheim | 1 | $113 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $97 |
| Noven Therapeutics, LLC | 4 | $87 |
| Corium, LLC | 5 | $80 |
| Neuronetics, Inc. | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$533,472
- LYBALVI$478,954
- CAPLYTA$175,565
- REXULTI$148,442
- ARISTADA INITIO$119,646
- Auvelity$108,451
- UZEDY$81,596
- Fanapt$79,776
- ABILIFY MAINTENA$77,267
- Austedo XR$49,363
- VRAYLAR$44,216
- ABILIFY ASIMTUFII$33,899
- TRINTELLIX$21,416
- COBENFY$15,789
- QUVIVIQ$15,472
- AUSTEDO$15,117
- PERSERIS$13,099
- INGREZZA$5,589
- LATUDA$3,282
- UBRELVY$150
How this compares
$1,157,069 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 174 | $254,309 |
| Austedo XrDeutetrabenazine | 23 | $121,501 |
| VraylarCariprazine Hcl | 57 | $79,012 |
| AristadaAripiprazole Lauroxil | 17 | $50,048 |
| TrintellixVortioxetine Hydrobromide | 82 | $39,766 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $38,831 |
| Abilify MaintenaAripiprazole | 17 | $37,757 |
| CaplytaLumateperone Tosylate | 23 | $35,969 |
| AuvelityDextromethorphan Hbr/Bupropion | 51 | $31,980 |
| UzedyRisperidone | 11 | $16,397 |
| QuviviqDaridorexant Hcl | 20 | $9,835 |
| VascepaIcosapent Ethyl | 14 | $3,264 |
| Mirtazapine | 159 | $2,268 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 43 | $2,206 |
| Quetiapine Fumarate | 211 | $2,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $230,249 | $292,066191 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $152,438 | $137,89834 claims |
| Alkermes, Inc.Aristada, Lybalvi | $254,664 | $88,87842 claims |
| AbbVieVraylar | $47,498 | $79,01257 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $23,292 | $39,76682 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $179,803 | $35,96923 claims |
| Axsome Therapeutics, Inc.Auvelity | $110,590 | $31,98051 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $15,805 | $9,83520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Anthony ZoghbiNew York$1.1M
- Ulla Kristina LaaksoNew York$890K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.